ReviewThe journal of physiological sciences : JPS2012
Oxytocin: a therapeutic target for mental disorders.
Review in The journal of physiological sciences : JPS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 78 citations in OpenAlex.
- Trial
- Intranasal administration of oxytocin increases compassion toward women.Social cognitive and affective neuroscience · 2015Trial
- Dose-dependent anxiolytic and antidepressant-like effects of chronic oxytocin in corticosterone-induced female mouse model of anxiety and depression.Biochemistry and biophysics reports · 2026Article
- Altered acetylcholine modulations and corticoaccumbal pathway in P11-linked social dysfunction.Molecular psychiatry · 2026Article
- Evaluation of the Hypothalamus-Hypophysis-Adrenal Axis in Male Rats Programmed by Gestational Protein Restriction.Cell biochemistry and function · 2025Article
- Plant hormone jasmonic acid reduces anxiety behavior in mice.Scientific reports · 2025Article
- The neurobiological impact of oxytocin in mental health disorders: a comprehensive review.Annals of medicine and surgery (2012) · 2025Review
- The Potential of a Robot Presence in Close Relationship to Influence Human Responses to Experimental Pain.Life (Basel, Switzerland) · 2025Article
- The role of biofield energy treatment on psychological symptoms, mental health disorders, and stress-related quality of life in adult subjects: A randomized controlled clinical trial.Journal of general and family medicine · 2023Article
- Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function.Frontiers in psychiatry · 2023Article
- Neuromodulatory functions exerted by oxytocin on different populations of hippocampal neurons in rodents.Frontiers in cellular neuroscience · 2023Review
- Oxytocin treatment improves dexamethasone-induced depression-like symptoms associated with enhancement of hippocampal CREB-BDNF signaling in female mice.Neuropsychopharmacology reports · 2022Article
- Oxytocin: Narrative Expert Review of Current Perspectives on the Relationship with Other Neurotransmitters and the Impact on the Main Psychiatric Disorders.Medicina (Kaunas, Lithuania) · 2022Review
- Protective Effects of Intranasally Administrated Oxytocin-Loaded Nanoparticles on Pentylenetetrazole-Kindling Epilepsy in Terms of Seizure Severity, Memory, Neurogenesis, and Neuronal Damage.ACS chemical neuroscience · 2022Article
- Gut microbiota: Linking nutrition and perinatal depression.Frontiers in cellular and infection microbiology · 2022Review
- Activation of septal OXTr neurons induces anxiety- but not depressive-like behaviors.Molecular psychiatry · 2021Article
- Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.International journal of molecular sciences · 2021Review
- Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances.International journal of molecular sciences · 2021Review
- Hypothalamic Neuropeptide Brain Protection: Focus on Oxytocin.Journal of clinical medicine · 2020Review
- The Role of Intranasal Oxytocin in Anxiety and Depressive Disorders: A Systematic Review of Randomized Controlled Trials.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We review here that oxytocin (OT) is released into blood and within distinct brain regions in response to stressful and social stimuli, and has been shown to have an antidepressant-like effect in animal studies. Clinical reports suggest OT to be a promising drug for psychiatric diseases such as depression, anxiety disorders, schizophrenia, and autism. OT may also have therapeutic potential in the treatment of major depressive disorders, even though OT administered into blood does not readily cross the blood-brain barrier. Physiological functions such as sexual activity and mating induce the release of OT in the central nervous system. A drug for the treatment of sexual dysfunction, sildenafil, enhances the electrically evoked release of OT from the posterior pituitary. This drug has antidepressant-like effects through activation of an OT signaling pathway. These results suggest that sildenafil may have promise as a potential antidepressant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.